What plasma surface functionalization actually does — and why it matters
Plasma surface functionalization is a dry, solvent-free process in which energetic ions, radicals, electrons, and photons generated in a plasma discharge interact with the top few nanometers of a substrate surface. The critical commercial advantage is precision without disruption: the plasma selectively introduces, removes, or rearranges chemical functional groups—carboxylic acids, hydroxyl, amine, epoxide, or fluorocarbon moieties—without altering the material’s structural bulk. This makes it uniquely suited to applications where surface performance must be engineered independently of bulk mechanical or optical properties.
Three principal processing regimes define the field. Low-pressure plasma (typically radio-frequency or microwave discharge, 10–100 Pa) offers the highest process control. Atmospheric-pressure plasma—delivered via dielectric barrier discharge, corona discharge, or plasma jet—eliminates vacuum infrastructure and enables inline industrial integration. Plasma polymerization, the third regime, fragments organic or organosilicon monomer vapors and re-deposits them as cross-linked, pinhole-free thin films with precisely tailored chemistry. As noted in the IOP Publishing-hosted 2022 Plasma Roadmap from Ohio State University, the field has been expanding to encompass plasma-enabled additive manufacturing, soft materials, electrification of chemical conversions, and data-driven plasma process optimization.
Plasma polymerization introduces organic or organosilicon monomer vapors into a plasma environment, where they are dissociated and re-deposited as cross-linked, pinhole-free thin films covalently bonded to the substrate. The deposited films carry specific functional groups—carboxyl, amine, epoxide, PEG-like, or fluorocarbon—determined by monomer selection, enabling durable and tunable surface chemistry that conventional wet chemistry cannot replicate.
Among retrieved patent and literature results, polymer substrates dominate, but metals, ceramics, and nanoparticles also appear—consistent with the broad substrate coverage reported by Nanyang Technological University’s 2021 review Plasma and Polymers: Recent Progress and Trends. The field has grown into a critical enabling platform for biomedical devices, filtration membranes, microelectronics, food packaging, and emerging plasma medicine applications.
Plasma surface functionalization modifies only the outermost atomic layers of a substrate—the top few nanometers—without disturbing bulk properties, using ionized gas to alter wettability, chemical composition, roughness, and biological response. The three principal processing regimes are low-pressure plasma (10–100 Pa), atmospheric-pressure plasma, and plasma polymerization.
From foundational filings to frontier applications: the innovation timeline
The plasma surface functionalization dataset spans publication dates from 2002 to 2025, representing at least two decades of documented patent and literature activity—a timeline that reveals three distinct developmental phases, each with a different dominant research question and commercial orientation.
The early foundational period (2002–2013) was dominated by plasma polymerization patents. Korea Institute of Science and Technology (KIST) filed multiple patents in Australia (2002, 2004) and Japan (2003) covering DC and RF discharge plasma polymerization to deposit hydrophilic or hydrophobic polymers on metals and other materials. Antithrombotic protein immobilization via plasma treatment on polyurethane was patented in Korea as early as 2003 by SK Evertech Co., Ltd. Biomolecule immobilization via atmospheric plasma was filed by the Flanders Institute for Technological Research (VITO) in 2010—an early signal of the bioconjugation application cluster that would intensify over the following decade.
The mid-stage development cluster (2014–2020) is characterized by intensive academic output and systematic study of specific process parameters—gas type, power, pressure, treatment time—and their effect on functional group density, wettability, cell adhesion, and protein adsorption. Notable milestones include hydrophilic plasma coating patents by Bioenergy Capital AG (2014), Harvard College’s CO₂-plasma biomolecule coupling patents (filed 2016–2017, published 2022 in Israel), and VITO’s plasma surface activation method (2017, EP).
The recent and emerging filing period (2021–2025) shows the broadest application diversity in the dataset. PLASMAPP Co., Ltd. filed a US design patent for a dedicated plasma implant surface treatment device in 2023. Samco Inc. published a Japanese patent on water plasma bonding of parylene-coated microfluidic substrates in December 2023. The most recent entry is a 2025 Brazilian pending application by Velico Medical, Inc. covering plasma pretreatment for spray drying of blood plasma proteins—a notable extension of plasma chemistry into biologic drug stability.
“The geographic distribution spans more than 15 countries with no single dominant corporate assignee—indicating that freedom to operate in core activation chemistry may be relatively open, but application-specific claims are being actively protected by academic spinouts and medical device companies.”
Four technology clusters driving the field
Patent and literature analysis identifies four principal technology clusters within plasma surface functionalization, each with a distinct mechanism, substrate preference, and commercial application profile. Understanding these clusters is essential for freedom-to-operate analysis and R&D positioning.
Cluster 1: Direct plasma activation and gas-phase etching
The most widely represented approach in the dataset exposes a substrate directly to plasma generated from reactive gases—O₂, Ar, N₂, air, SF₆, CF₄, or C₄F₈—to etch the surface, introduce polar functional groups, and increase wettability. Oxygen plasma is the most commonly used variant, generating –OH, –COOH, and –C=O groups. Research from CNR Italy (2022) demonstrated that RF oxygen and argon/oxygen plasma treatment of poly(butylene succinate) films reduces contact angle from 80° to less than 5°, a transformation relevant to biodegradable packaging and biomedical substrate preparation. According to ACS Publications, fluorinated gas plasmas (SF₆, CF₄, C₄F₈) generate superhydrophobic surfaces by depositing fluorocarbon moieties—the inverse engineering problem.
Oxygen plasma treatment of poly(butylene succinate) (PBS) biodegradable films reduces water contact angle from 80° to less than 5°, as demonstrated by CNR Italy (2022) using RF oxygen and argon/oxygen plasma. Fluorinated gas plasmas (SF₆, CF₄, C₄F₈) produce the opposite effect, generating superhydrophobic surfaces by depositing fluorocarbon moieties.
Cluster 2: Plasma polymerization and thin-film deposition
Organic or organosilicon monomer vapors introduced into a plasma environment are dissociated and re-deposited as cross-linked, pinhole-free thin films covalently bonded to the substrate. The deposited films carry specific functional groups determined by monomer selection. A 2024 study from Empa (Swiss Federal Laboratories) introduced near-plasma chemistry (NPC)—a mesh-mediated approach that selectively excludes ions while retaining reactive neutrals at the plasma-sheath boundary—enabling highly porous SiOx coatings and controlled PTFE activation at low temperatures. This represents a meaningful architectural shift toward more chemically defined reactions and directly addresses the aging and hydrophobic recovery problem documented across multiple studies in the dataset.
Cluster 3: Plasma-assisted biomolecule immobilization and bioconjugation
This cluster uses plasma-activated surfaces as platforms for covalent or non-covalent attachment of proteins, antibodies, peptides, and other biomolecules. The plasma step generates a high density of reactive anchor groups, which then serve as coupling sites in subsequent wet chemistry steps. Harvard College’s CO₂-plasma biomolecule coupling patents (2022, Israel) target hemodialysis and diagnostic assay applications. A 2013 study from CRCHUM (Canada) demonstrated that primary amine-rich plasma-polymerized coatings serve as universal coupling platforms for star-PEG grafting, achieving near-zero platelet adhesion—a result directly relevant to blood-contacting medical device development.
Explore the full plasma surface functionalization patent landscape in PatSnap Eureka — map assignees, claims, and white-space opportunities.
Analyse Patents with PatSnap Eureka →Cluster 4: Cold atmospheric plasma (CAP) for living systems and indirect treatment
Cold atmospheric plasma operates at or near ambient temperature and pressure, making it compatible with biological tissues, living cells, and temperature-sensitive substrates. CAP generates reactive oxygen and nitrogen species (RONS), UV photons, electric fields, and charged particles. A significant sub-branch involves plasma-activated liquids (PAL/PAW), where reactive species are transferred to an aqueous medium for indirect application—enabling treatment of geometrically complex or internal surfaces inaccessible to direct plasma exposure. Research from Monash University Malaysia (2023) covers plasma jet, DBD, and glow discharge techniques for plasma-activated water (PAW) generation, including surface disinfection, seed germination enhancement, and surface cooling applications. As documented by WHO-aligned antimicrobial resistance research, the non-antibiotic antimicrobial mechanism of CAP is attracting increasing clinical attention.
Application domains: where plasma functionalization is winning
Plasma surface functionalization is not a single-market technology. The dataset reveals six distinct application domains, each with its own maturity level, key institutions, and commercial dynamics.
Biomedical implants and dental applications
The largest concentration of research in the dataset addresses plasma treatment of implant surfaces—titanium, PEEK, polyurethane, PDMS—to enhance osseointegration, protein adsorption, and cell adhesion. Multiple studies confirm that oxygen and argon plasma treatments drive contact angles toward superhydrophilicity and significantly increase bone-to-implant contact in vivo. University Hospital Tübingen (2022) demonstrated that Ar and O₂ plasma modification of fused filament fabricated PEEK implants targets cell adhesion and osteogenic differentiation. PLASMAPP Co., Ltd. (Korea) filed a US design patent in 2023 for a dedicated commercial plasma implant treatment device, signaling Korean commercial interest in the dental and medical device hardware market.
Filtration membranes and water treatment
Plasma modification of polymer membranes—polyethylene, polyethersulfone, PET—to improve antifouling performance and hydrophilicity is a well-developed application domain. National Taiwan University of Science and Technology (2020) demonstrated plasma polymerization of ethylene oxide-containing monomers onto PE membranes for antifouling performance against mammalian cells and proteins. Deakin University’s 2018 mechanistic review spans low-pressure and atmospheric plasma modification for water desalination and wastewater membrane applications, as catalogued in databases maintained by ACS Publications.
Plasma medicine: wound healing, oncology, and dermatology
CAP-based plasma medicine is a fast-growing application vertical. Research from the University of Regensburg (2013) demonstrated CAP induction of IL-6, IL-8, and TGF-β1/β2 gene expression in fibroblasts, with demonstrated in vivo wound healing acceleration. INP Greifswald/ZIK Plasmatis (2019) published a clinical-stage review of CAP for anti-itch, antimicrobial, anti-inflammatory, and proapoptotic applications. The Royal College of Surgeons of England (2022) produced a comprehensive review of CAP for wound healing, inflammatory skin disorders, and infectious skin conditions.
Cold atmospheric plasma (CAP) has been studied for wound healing, inflammatory skin disorders, infectious skin conditions, and cancer treatment. Research from the University of Regensburg (2013) demonstrated that CAP induces IL-6, IL-8, and TGF-β1/β2 gene expression in fibroblasts and accelerates wound healing in vivo. INP Greifswald (2019) documented clinical-stage applications for anti-itch, antimicrobial, anti-inflammatory, and proapoptotic effects.
Food packaging and agricultural applications
Plasma surface treatment of packaging polymers (PET, PVC, PE) for barrier enhancement, wettability tuning, and anti-adhesion properties is represented across multiple dataset entries. The State University of Sao Paulo (2018) demonstrated nitrogen and SF₆ plasma immersion ion implantation producing controllable hydrophilic/hydrophobic PET surfaces for food packaging. Czech Technical University (2021) covers packing material decontamination, seed disinfection, and shelf life extension. Plasma-activated water (PAW) is gaining traction in agricultural applications, including seed germination enhancement and surface decontamination.
Microfluidics, lab-on-chip, and analytical devices
Plasma activation is the standard method for bonding PDMS microfluidic chips to glass and for hydrophilizing channel walls. Samco Inc.’s 2023 Japanese patent on water plasma (H₂O plasma) bonding of parylene-coated PDMS microfluidic substrates opens new routes for fabricating complex multilayer microfluidic architectures without adhesives or thermal compression. University of Wisconsin-Madison (2014) demonstrated spatial mapping of oxygen plasma penetration into microchannels and its impact on cell culture uniformity.
Energy storage — an emerging frontier
Hanbat National University (2023) demonstrated that O₂ atmospheric plasma introduces carbonyl functional groups into a PVA gel-polymer electrolyte matrix, achieving greater than 2× improvement in supercapacitor performance metrics. This application domain was previously underrepresented in plasma surface functionalization research and represents a genuine white-space opportunity for materials companies working in solid-state energy storage.
Track emerging plasma functionalization patent filings across energy storage, plasma medicine, and near-plasma chemistry in real time.
Explore Patent Data in PatSnap Eureka →Geographic and assignee landscape: distributed innovation, targeted IP
The plasma surface functionalization patent and literature dataset spans more than 15 countries, with no single corporate actor dominating the field—a structure that has significant implications for freedom-to-operate analysis and partnership strategy.
Among patent records retrieved (10 patents/patent applications), the represented jurisdictions include AU (3 records), PL (2), IL (2), KR (1), EP (1), US (1), JP (1), and BR (1). The EP, PL, and IL entries reflect PCT-routed international filings originating from Belgium (VITO) and the United States (Harvard College) respectively, indicating that the primary innovation jurisdictions are Europe and the US, with Korea active in foundational plasma polymerization patents.
Among the approximately 65 literature records, the most heavily represented institutions include Korea (KIST, Sejong University, Pusan National University, KAIST, Korea Institute of Fusion Energy), Germany (INP Greifswald, University of Tübingen, University of Freiburg), Slovenia (Jozef Stefan Institute, appearing in at least 5 separate records), Italy (CNR, multiple institutes), Taiwan (National Taiwan University of Science and Technology, National Cheng Kung University), and Switzerland (Empa). As catalogued by WIPO‘s global IP statistics, the distribution of more than 40 distinct institutions confirms that plasma surface functionalization is not dominated by a single corporate actor but rather spread across academic research groups and a smaller number of specialized commercial entities.
The Jozef Stefan Institute (Slovenia) is the single most frequently appearing institution in the plasma surface functionalization dataset, appearing in at least 5 separate records covering surface chemistry of polyamides, PET, polyurethane, and metal surfaces. Empa (Switzerland) is notable for advancing near-plasma chemistry concepts. VITO (Belgium) holds active EP patents on plasma surface activation and biomolecule immobilization. Harvard College (US) holds active IL patents on CO₂-plasma biomolecule coupling.
Emerging directions and strategic implications for 2026
Six innovation vectors are apparent from the most recent filings and publications (2022–2025) in the dataset, each with distinct strategic implications for R&D investment, IP positioning, and commercial development.
1. Near-plasma chemistry (NPC) for precision functionalization
Empa’s 2024 mesh-mediated approach selectively excludes ions while retaining reactive neutrals at the plasma-sheath boundary, enabling highly porous SiOx film deposition at low temperature and controlled PTFE activation. This is a technically differentiated approach to achieving more precisely defined surface chemistries than conventional direct plasma exposure—directly addressing the aging and hydrophobic recovery problem documented across multiple studies. Companies seeking durable, stable functionalization should assess NPC as a white-space opportunity.
2. Water plasma for microfluidic bonding
Samco Inc.’s 2023 Japanese patent on water plasma (H₂O plasma) as a bonding medium for parylene-over-PDMS microfluidic chips opens new routes for fabricating complex multilayer microfluidic architectures without adhesives or thermal compression. This approach is particularly relevant for organ-on-chip and point-of-care diagnostic device manufacturers seeking scalable, solvent-free assembly processes.
3. Plasma functionalization for energy storage materials
Atmospheric plasma treatment of PVA gel-polymer electrolytes for supercapacitors, as demonstrated at Hanbat National University (2023), indicates expansion of plasma surface engineering into the energy materials space. The greater than 2× improvement in supercapacitor performance metrics achieved through O₂ plasma-introduced carbonyl functional groups in the PVA matrix is a result that warrants attention from solid-state battery and supercapacitor developers. This is a previously underrepresented application domain in the patent record.
4. Plasma-activated water as a delivery format
The growing body of PAW/PAL research—Monash University (2023), Ajou University (2021), George Washington University (2020)—indicates increasing interest in plasma-generated reactive species delivered indirectly through aqueous media. Companies with existing liquid delivery infrastructure (irrigation systems, medical irrigation devices, cosmetic dispensing) should explore PAW integration as a minimal-investment route into plasma-enabled products without capital investment in plasma hardware at the point of use.
5. Plasma pretreatment for biologic drug stability
The 2025 Velico Medical Brazilian application on plasma pretreatment of blood plasma proteins prior to spray drying represents a notable new direction—applying plasma chemistry to extend the shelf life and recovery of biologics. This extension of plasma surface engineering into pharmaceutical manufacturing processes is not yet represented in the mainstream patent record and may indicate an emerging application cluster.
6. Data-driven plasma process optimization
The 2022 Plasma Roadmap from Ohio State University identifies data-driven plasma science as a new priority area, suggesting that machine learning-assisted process parameter optimization for surface functionalization is an emerging research direction not yet heavily represented in the patent record but expected to grow. R&D teams building plasma process control systems should monitor this space for early patent filings from academic groups in the US and Europe.
The atmospheric-pressure plasma segment—delivered via dielectric barrier discharge, corona discharge, or plasma jet—requires no vacuum infrastructure, enabling inline industrial integration. The 2022 Plasma Roadmap (Ohio State University) identifies data-driven plasma science as a new priority area, with machine learning-assisted process parameter optimization expected to grow as a research and patent-filing direction.
From a strategic IP perspective, the biomedical devices domain represents the dominant and most active patent-filing domain in the dataset. Companies developing implantable devices, diagnostic platforms, or cell culture consumables should assess plasma functionalization not merely as a processing step but as an IP-generating surface engineering platform with significant freedom-to-operate complexity, given active patents held by Harvard College (IL), VITO (EP), and PLASMAPP (US). The atmospheric-pressure plasma segment is outpacing low-pressure plasma in application versatility—R&D teams in packaging, textiles, and wood treatment should prioritize atmospheric plasma process development where capital cost and throughput are paramount.